跳转至内容
Merck
CN

主要文件

查看所有文档

C3809

头孢他啶 水合物

90.0-105.0%, contains ~10% sodium carbonate as stabilizer

别名:

1-\ [[(6R,7R)-7-\ [\ [(2Z)-（2-氨基-4-噻唑基）\ [（1-羧基-1-甲基乙氧基）亚氨基] 乙酰基] 氨基]-2-羧基-8-氧代-5-硫杂-1-氮杂双环 \ [4.2.0] 辛-2-烯-3-基] 甲基] 吡啶

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C22H22N6O7S2 · xH2O
化学文摘社编号:
120618-65-7
分子量:
546.58 (anhydrous basis)
NACRES:
NA.85
PubChem Substance ID:
24892644
UNSPSC Code:
51284108
MDL number:
MFCD00153936
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

200

assay

90.0-105.0%

form

powder or crystals

contains

~10% sodium carbonate as stabilizer

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria

mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

SMILES string

[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C([O-])=O)c4csc(N)n4)C(O)=O

InChI

1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1

InChI key

NMVPEQXCMGEDNH-TZVUEUGBSA-N

General description

广谱抗生素；第三代头孢菌素
化学结构式：β-内酰胺

Application

用于研究青霉素结合蛋白特别是 PBP3 的表达、结合和抑制对细菌细胞壁粘肽合成的影响。
用头孢他啶水合物研究青霉素结合蛋白特别是 PBP3 的表达、结合和抑制对细菌细胞壁粘肽合成的影响。也用于细菌敏感性研究 和选择相关突变菌落。

Biochem/physiol Actions

头孢类抗生素如头孢他啶可破坏细菌细胞壁肽聚糖层的合成。

Other Notes

将容器密闭保存在干燥和通风良好的地方。置干燥处保存

Still not finding the right product?

Explore all of our products under 头孢他啶 水合物

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Eye Irrit. 2 - Resp. Sens. 1 - Skin Sens. 1

存储类别

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
WXBF8549V
0000519785
0000519784
0000519783
0000519781

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Neang S Ly et al.
The Journal of antimicrobial chemotherapy, 70(5), 1434-1442 (2015-02-26)
Colistin is an 'old' drug, which is being increasingly utilized due to limited therapeutic options. However, resistance emergence during monotherapy is concerning. Here, our objective was to optimize colistin combinations against Pseudomonas aeruginosa by profiling the time course of synergistic
Kristopher R Genschmer et al.
Cell, 176(1-2), 113-126 (2019-01-12)
Here, we describe a novel pathogenic entity, the activated PMN (polymorphonuclear leukocyte, i.e., neutrophil)-derived exosome. These CD63+/CD66b+ nanovesicles acquire surface-bound neutrophil elastase (NE) during PMN degranulation, NE being oriented in a configuration resistant to α1-antitrypsin (α1AT). These exosomes bind and
Melissa D Barnes et al.
mBio, 9(6) (2018-12-13)
Pseudomonas aeruginosa produces a class C β-lactamase (e.g., PDC-3) that robustly hydrolyzes early generation cephalosporins often at the diffusion limit; therefore, bacteria possessing these β-lactamases are resistant to many β-lactam antibiotics. In response to this significant clinical threat, ceftolozane, a
查看所有相关文献

全球贸易项目编号

货号GTIN
C3809-1G04061833486436
C3809-5G04061833486443